Open Access Open Access  Restricted Access Subscription or Fee Access

Summarizing assessment on pharmacological involvements in Obesity: Barrier and Handling

Rajat Sharma, Monika Singh, Moumita Barman

Abstract


Pervasiveness related overheavy as well as slenderness can intensification ubiquitously over creation. Communal morbidities connected through overweightness, predominantly hypertension, diabetes and heart disease have an impression on societal and monetarist organizations. Suitable existence and behaviour intercessions are tranquil the decisive foundation to weight loss accomplishment, but continuing such a vigorous existence is tremendously interesting. Plentiful accepted ingredients discovered for the overweightness conduct budding and extensively used to encourage the expansion of anti-obesity goods. The heaviness loss section is single the foremost promoters complete income of the nutritional enhancements marketplace. By this assessment, the action of obesity belongings dissimilar alimentary or herbal goods, and energetic constituents as well as apparatuses with accomplishment in contradiction of overweightness will be deliberated.

Keywords: Weight loss, Anti-obesity, Leptin, Sex hormone, Enzyme.


Full Text:

PDF

References


Dietz WH, Bellizzi MC. Introduction: the use of body mass index to assess obesity in children. The American journal of clinical nutrition. 1999 Jul 1;70(1):123S-5S.

Mandal, Dr. Ananya. “Obesity and Hormones.” News, 27 Feb. 2019, https://www.news-medical.net/health/Obesity-and-Hormones.aspx.

Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. International Journal of Obesity. 2003 Dec;27(3):S17-21.

Villarroya F, Peyrou M, Giralt M. Transcriptional regulation of the uncoupling protein-1 gene. Biochimie. 2017 Mar 1;134:86-92.

Joshua S., et al. “The Influence of an Obesogenic Diet on Oxysterol Metabolism in C57BL/6J MICE.” Cholesterol, Hindawi, 5 Feb. 2014.

Louise E. Olofsson, Marju Orho-Melander, Lena William-Olsson, Kajsa Sjöholm, Lars Sjöström, Leif Groop, Björn Carlsson, Lena M. S. Carlsson, Bob Olsson, CCAAT/Enhancer Binding Protein α (C/EBPα) in Adipose Tissue Regulates Genes in Lipid and Glucose Metabolism and a Genetic Variation in C/EBPα Is Associated with Serum Levels of Triglycerides, The Journal of Clinical Endocrinology & Metabolism, Volume 93, Issue 12, 1 December 2008, Pages 4880–4886.

Anubhuti, Arora S. Leptin and its metabolic interactions–an update. Diabetes, Obesity and Metabolism. 2008 Nov;10(11):973-93.

Mandal, Dr. Ananya. “Obesity and Hormones.” News, 27 Feb. 2019.

Baskaran, Gunasekaran, et al. “HMG-COA Reductase Inhibitory Activity and Phytocomponent Investigation of Basella Alba Leaf Extract as a Treatment for Hypercholesterolemia.” Drug Design, Development and Therapy, U.S. National Library of Medicine, 14 Jan. 2015.

Steinberg, Gregory R., and David Carling. “AMP-Activated Protein Kinase: The Current Landscape for Drug Development.” Nature News, Nature Publishing Group, 13 Mar. 2019.

Hao, Yang, et al. “Acetyl-COA: An Interplay between Metabolism and Epigenetics in Cancer.” Frontiers, Frontiers, 2 Nov. 2022.

D Kinlen, D Cody, D O’Shea, Complications of obesity, QJM: An International Journal of Medicine, Volume 111, Issue 7, July 2018, Pages 437–443.

S.D.H. Malnick, H. Knobler, The medical complications of obesity, QJM: An International Journal of Medicine, Volume 99, Issue 9, September 2006, Pages 565–579.

Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006 Feb 14;113(6):898-918.

Motta AB. The role of obesity in the development of polycystic ovary syndrome. Curr Pharm Des. 2012;18(17):2482-91.

Chatterjee B, Suri J, Suri JC, Mittal P, Adhikari T. Impact of sleep-disordered breathing on metabolic dysfunctions in patients with polycystic ovary syndrome. Sleep Medicine. 2014 Dec 1;15(12):1547-53.

Vrbikova J, Hainer V. Obesity and polycystic ovary syndrome. Obesity facts. 2009;2(1):26-35.

Fabricatore AN, Wadden TA. Treatment of obesity: an overview. Clinical Diabetes. 2003 Mar 22;21(2):67-73.

Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature. 2000 Apr;404(6778):672-7.

Wirth A, Wabitsch M, Hauner H. The prevention and treatment of obesity. Dtsch Arztebl Int. 2014 Oct 17;111(42):705-13.

Eldalo AS, Alotaibi MN, Alenazi TO, Albogami HA, Mohamed KM. Use of herbal medicines in the treatment of obesity in Taif, Saudi Arabia. Saudi Journal of Medicine & Medical Sciences. 2017 May;5(2):149.

Liu Y, Sun M, Yao H, Liu Y, Gao R. Herbal medicine for the treatment of obesity: an overview of scientific evidence from 2007 to 2017. Evidence-Based Complementary and Alternative Medicine. 2017 Jan 1;2017.

Ogunremi, O.M., Grebe, G.A., Ibrahim, I.M. et al. Identification of promising multi-targeting inhibitors of obesity from Vernonia amygdalina through computational analysis. Mol Divers (2022).

Adekanmi AA, Adekanmi UT, Adekanmi AS, Oyekanmi HA. Assessment of Proximate Composition and Phytochemical Properties of Bitter Leaf (Vernonia Amygdalina) and Water Leaf (Talinum Triangular). United International Journal for Research & Technology. 2020;1(9):13-21.




DOI: https://doi.org/10.37591/tdd.v9i3.1256

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Trends in Drug Delivery